Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-03-10 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
总经理工作细则
Governance Information Classification · 95% confidence The document is titled as "总经理工作细则" which translates to "General Manager Work Rules" or "General Manager Operational Guidelines". It details the qualifications, responsibilities, authority, meeting procedures, and accountability of the company's general manager. There is no mention of financial data, reporting periods, regulatory filings, or shareholder information. It is a governance-related internal document outlining management roles and procedures rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-03-10 Chinese
董事、高级管理人员薪酬管理办法
Remuneration Information Classification · 95% confidence The document is titled as a management method for remuneration of directors and senior management personnel of the company. It details principles, composition, standards, management, and payment of remuneration for directors and senior executives. There is no financial data, no report on financial performance, no voting results, no legal proceedings, no capital changes, no earnings data, no presentations, and no regulatory certifications. The content is focused on governance and internal rules regarding compensation management. This fits the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2025-03-10 Chinese
关于注销回购股份并减少注册资本的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from 普洛药业股份有限公司 regarding the cancellation of repurchased shares and the consequent reduction of registered capital. It details the share repurchase plan, the number of shares repurchased and to be cancelled, the impact on share capital, and the authorization process. The document is a formal notice about a capital structure change due to share cancellation following a buyback. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a specific announcement about share cancellation and capital reduction, which fits the category of Share Issue/Capital Change (SHA). The document length is 1901 characters, which is relatively short and consistent with an announcement rather than a full report.
2025-03-10 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled "普洛药业股份有限公司2024 年年度报告全文" which translates to "Apeloa Pharmaceutical Co., Ltd. 2024 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes signed financial statements and an audit report, confirming it is the full annual report. Therefore, the document is classified as an Annual Report (10-K). FY 2024
2025-03-10 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th meeting of the 9th Board of Directors of 普洛药业股份有限公司. It lists multiple agenda items that were approved, including the 2024 Annual Report, Board Work Report, General Manager Work Report, Financial Statements, Internal Control Evaluation Report, Profit Distribution Plan, ESG Report, and other governance-related matters. The document repeatedly states that these resolutions still need to be submitted to the shareholders' meeting for approval. The document is not the actual annual report or financial statements but a board meeting resolution announcement. It is a typical Board/Management Information announcement about board decisions and approvals. The document length is short (1647 characters), and it does not contain the full reports or financial data, only the resolutions passed. Therefore, the correct classification is Board/Management Information (MANG).
2025-03-10 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 普洛药业股份有限公司 regarding the approval of various reports and proposals related to the 2024 fiscal year, including the 2024 Annual Report, Supervisory Board Work Report, Financial Statements, Internal Control Evaluation Report, Profit Distribution and Capital Reserve to Share Capital Plan, and other governance matters. The document states that these approvals are subject to further approval by the shareholders' meeting. The document is relatively short (1376 characters) and serves as an official announcement of the Supervisory Board's meeting resolutions rather than the full reports themselves. It does not contain detailed financial data or the full annual report but rather the decisions and approvals made. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and approvals, not the full Annual Report (10-K) or other detailed reports.
2025-03-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.